First-of-its-Kind cancer vaccine trial targets rare liver tumor
NCT ID NCT04248569
Summary
This early-stage study is testing a new personalized vaccine designed to teach the immune system to attack fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer. The vaccine is given alongside two immunotherapy drugs (nivolumab and ipilimumab) to boost the body's cancer-fighting response. The main goals are to check if the combination is safe and to see if it triggers the desired immune reaction in patients with advanced FLC or related solid tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROLAMELLAR HEPATOCELLULAR CARCINOMA (FLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.